XML 125 R111.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Concentrations - Additional Information (Detail) $ in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2015 USD ($) | Dec. 31, 2014 USD ($) Project | Dec. 31, 2013
Concentration Risk [Line Items] |  |  |
Concentration risk, customer | There is no single commercial payor that accounted for more than 10% of total consolidated accounts receivable at December 31, 2015 and 2014. |  |
Accounts Receivable | Government-based Programs, Medicare and Medicaid |  |  |
Concentration Risk [Line Items] |  |  |
Concentration Risk, Percentage | 80.00% |  |
Accounts Receivable | Product Concentration Risk | Minimum |  |  |
Concentration Risk [Line Items] |  |  |
Concentration Risk, Percentage | 10.00% | 10.00% |
U.S. dialysis and related lab services | Sales Revenue Services Net | Government-based Programs, Medicare and Medicaid |  |  |
Concentration Risk [Line Items] |  |  |
Concentration Risk, Percentage | 66.00% | 67.00% | 66.00%
Accounts receivable, and other receivables, from Medicare and Medicaid-assigned plans | $ | $ 827,258 | $ 705,532 |
HealthCare Partners (HCP) |  |  |
Concentration Risk [Line Items] |  |  |
Number of health plans | Project |  | 3 |
HealthCare Partners (HCP) | Sales Revenue Services Net | Government-based Programs, Medicare and Medicaid |  |  |
Concentration Risk [Line Items] |  |  |
Concentration Risk, Percentage | 70.00% | 71.00% | 69.00%
HealthCare Partners (HCP) | Sales Revenue Services Net | Product Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration Risk, Percentage | 61.00% | 64.00% | 67.00%
HealthCare Partners (HCP) | Accounts Receivable | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration Risk, Percentage | 71.00% | 73.00% |

X
- Definition Description of risks that arise due to the volume of business transacted with a three health plans. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes "Information about Major Customers" that may be disclosed elsewhere (for instance, segment disclosures). + References No definition available. + Details
Name: | dva_ConcentrationRiskNumberOfHealthPlans
Namespace Prefix: | dva_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes "Information about Major Customers" that may be disclosed elsewhere (for instance, segment disclosures). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6327-108592 + Details
Name: | us-gaap_ConcentrationRiskCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ConcentrationRiskLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition This item represents disclosure of all significant concentrations of credit risk or market risk arising from the subject financial instrument (as defined), whether from an individual counterparty or groups of counterparties. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 3 -Subparagraph a, b -Article 5 + Details
Name: | us-gaap_FairValueConcentrationOfRiskAccountsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=dva_USDialysisAndRelatedLabServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueServicesNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=dva_HealthcarePartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |